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ABSTRACT
Limited cell dose hampers wider use of cord blood transplantation (CBT). By depleting plasma but not RBC
during processing, nucleated cell (NC) loss is reduced to <0.1% which increases significantly the proportion
of high cell dose products—3-fold for products with NC >200  107. Clinical outcome for plasma depleted
(PD) CBT was previously unavailable. A retrospective audited analysis was performed on 118 PD CBT, with
mean and median NC doses of 7.6 107/kg and 5.6 107/kg, respectively, for this mostly pediatric population.
The median times to engraftment and engraftment rates for ANC 500 and platelet 20K were 22 and 50 days,
respectively, and 90%  3% and 77%  5%, respectively. The incidences of grade III-IV acute graft-versus-
host disease (aGVHD) and extensive chronic GVHD (cGVHD) were 13%  4% and 17%  6%, respectively.
Relapse rate for malignancies was 25%  6% and 100-day treatment-related mortality (TRM) was 16%  3%.
With a median follow-up of 557 days, the 1-year overall survival and relapse-free survival are 65%  5% and
51%  6%, respectively. These results demonstrate that PD CBT is safe and effective, and that eliminating
RBC reduction or depletion improves cell recovery during CB processing, resulting in a larger proportion of
the inventory with high NC number.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Many patients in need of a hematopoietic cell
ransplant (HCT) do not have a matched-related or
nrelated bone marrow or peripheral blood donor,
lthough there are currently over 10 million volun-
eers registered worldwide [1]. If a patient belongs to
n ethnic minority, the probability of not ﬁnding an
LA-matched unrelated donor is even greater. More-
ver, because the search process for an adult donor
ften takes months, a signiﬁcant proportion of pa-
ients will expire, or become higher risk, or ineligible t
346or transplantation while waiting for the completion of
donor search [2]. For patients who cannot ﬁnd a
uitably HLA-matched adult donor, cord blood (CB)
s a viable option [1]. As CB products are HLA-
yped, tested for lack of infectious agents, and
tored, they are immediately available upon request
nd can be shipped to transplant centers around the
orld. Cord blood transplantation (CBT) has been
eported to be associated with a lower incidence of
cute graft-versus-host disease (aGVHD), and par-
ial HLA match between the donor and recipient is
olerable [1].
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Plasma-Depleted Cord Blood Transplantation 1347Favorable results following CBT have contributed
o changes in clinical practice. In the pediatric setting,
BT is now an established practice and may soon
urpass the number of unrelated volunteer donor
ransplants, as is already the case in Japan. In the adult
etting, adaptation has been slower due to the cell-
ose limitation. Strategies focused on overcoming this
imitation are under intense investigation including
he utilization of double CB grafts [3-7], avoidance of
ostthaw wash [8-12], and the combination of unre-
ated CB with haploidentical peripheral blood stem
ells [13], all of which have shown promising engraft-
ent and survival results.
Because stem and progenitor cells are inevitably
ost during red cell depletion/reduction processing
RD) of CB products with nucleated cell losses of 14%
o 42% [14,15,16,17], we have developed and evalu-
ted the use of CB products from which plasma but
ot red cells have been removed to minimize cell loss.
large CB inventory of 26,000 CB products pro-
essed with this novel technology has now been estab-
ished, with 88% from minority donors.
ATIENTS, MATERIALS, AND METHODS
tandards and Regulations
All applicable state, federal, national, and interna-
ional regulations and standards were followed, in-
luding standards for Foundation for the Accredita-
ion of Cellular Therapy and AABB.
ollection, Donation, Plasma Depletion
rocessing, Testing, Cryopreservation,
nd Storage
CB was collected under institutional review board
pproval and donor informed consents. Donors with
enetic or behavioral risks on medical history were
xcluded from donation. Trained collectors harvested
B by closed system collection blood bag containing
itrate-phosphate buffer-dextrose. Collected CB units
ere shipped at room temperature (15°C to 26°C) to
rocessing laboratories using validated containers.
lasma depletion processing was performed and com-
leted in a closed system within 48 hours of collection.
B units were centrifuged in the original collection
ag at 1680  g for 10 minutes at room temperature
ollowed by variable amounts of plasma removed into
n attached empty bag using a plasma expressor to
each a ﬁnal CB volume of 60-84 mL before adding
ryoprotectant solution. For larger units, the products
ere stored in 2 bags. Postprocessing, samples were
aken for complete blood count with differential and
ucleated red blood cell enumeration with a Sysmex-
600, trypan blue viability, hemoglobinopathy screen-
ng, ABO/Rh typing, HLA typing using DNA-based
ethods and CD34 cell enumeration with the Pro- tount Method using a Becton Dickinson (Franklin
akes, NJ) FAC-SCAN. Colony-forming unit (CFU)
ssays were added since 2004, respectively. The col-
ection bag(s) containing the remaining cellular por-
ion was then connected in a sterile manner to a Baxter
Deerﬁeld, IL) Cryocyte® freezing bag via a sterile
ocking device. The plasma depletion (PD) CB prod-
ct was then precooled at 4°C for at least 30 minutes
rior to cryoprotectant addition. The cryopreserva-
ion solution consisting of 50% DMSO and 10%
extran Sulfate (Gentran-40), prechilled to 4°C, was
hen added to a ﬁnal concentration of 5% to 10%
MSO using a syringe pump, with the CB and the
ryoprotectant wrapped between cool packs during
his 20-minute period. After cryoprotectant addition,
B products were subjected to controlled rate freez-
ng from 4°C to50°C at1°C per minute, and then
rom 50°C to 90°C at 10°C per minute in MVE
RF 2100 controlled rate freezers. All control rate
reezing curves were reviewed to ensure that at no
oint from 4°C to 50°C did the product experience
cooling rate in excess of 5°C per minute. After
ttaining 90°C, the CB products were immediately
ransferred from the controlled rate freezer to liquid
itrogen tanks.
Products with maternal or CB reactive for HIV-
/2, HTLV-I/II, HCV, and HBsAg serology, positive
IV or HCV NAT results, positive bacterial or fungal
ulture, homozygosity or double heterozygosity for
emoglobinopathy mutations were excluded from
ransplantation inventory.
haw Procedure, Conditioning, and GVHD
rophylaxis Regimens
Prior to infusion of the thawed CB, the product
as washed in 67 instances (56.8%), whereas 50 prod-
cts were infused without washing (42.4%) per trans-
lant center’s decision (information unavailable for 1
nit). When washing was performed, transplant cen-
ers either used their own protocol or followed the
temCyte recommended wash protocol. As a CB bank
tudy with many transplant centers (TC), various con-
itioning and GVHD prophylaxis regimens were
sed.
omparisons of Postprocessing Cell Dose
etween PD and Red Cell Depleted/Reduced (RD)
B Inventories
Postprocessing and postthaw recovery rates were
etermined for plasma depletion. Although different
ecovery rates for RD have been reported
14,15,17,18], no data exist for a rigorous comparison
f actual CB inventories. The National Marrow Do-
or Program (NMDP) CB inventory was chosen to
tudy if there exists any difference in cell dose between
he 2 types of inventories, because the NMDP CB
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R. Chow et al.1348anks have the largest national inventory of CB, with
banks that practice PD processing and 16 that prac-
ice RD processing. As of June 31, 2006, there were
0,912 PD CB and 38,819 RD CB for a combined
nventory of 49,731 units [19]. Comparison was per-
ormed between the PD CB and RD CB inventories
o assess any differences in proportion of high total
ucleated cell (TNC) CB units.
utcome Data Collection Rate, Source, Audits,
ata Subsets, and Statistical Analysis
Outcome Data Collection Rate and Sources. A retro-
pective analysis was performed that included all pa-
ients with engraftment and/or survival data trans-
lanted with PD CB from November 2001, the time
f the ﬁrst transplant performed with plasma-depleted
B, to the cutoff date of April 28, 2005. Two CB
anks (StemCyte US and Taiwan CBB) provided all
he PD units for the analysis. The full cohort of all 118
BT using PD CB constituted the “All Patients”
roup. When patients with prior transplants or trans-
lanted during relapse were excluded in the engraft-
ent and survival analysis to assess outcome without
he most advanced risk patients, the remaining subset
ad 98 such patients and are identiﬁed as “Remission
irst Transplant Patients,” and this cohort contained
oth patients with benign indications and patients
ith malignant indications transplanted during remis-
ion. Transplants using CB products that were washed
ostthaw were compared against products that were
nfused without wash. Transplants for malignant in-
ications were also analyzed separately from trans-
lants for benign indications. Patients were also di-
ided by body weight, 50 kg and 50 kg. Last,
ransplants using single CB were compared with
ransplants using double cords.
Data Audit. Data for CBT facilitated by the Na-
ional Marrow Donor Program (NMDP) were sup-
lied and audited by NMDP. For non-NMDP facil-
tated transplants, outcome data were obtained
irectly from the respective transplant centers. Addi-
ional data not contained in the NMDP forms were
licited directly from all transplant centers. Data re-
arding each patient were then sent to the respective
ransplant centers to audit accuracy. StemCyte U.S.
nd Taiwan subsets were analyzed individually and
ompared to the NMDP subset to assess the impact of
he difference in data collection rates on outcome data
nd to evaluate the possibility of favorable reporting
ias. Last, the auditing services of the Center for
nternational Blood and Marrow Transplant Research
CIBMTR) were retained to perform on-site audits
or 85 patients transplanted with PD CB products.
Data Subsets. Double CBT, nonmyeloablative or
educed-intensity CBT, and combination CB and
aploidentical peripheral blood transplant accounted
or 21, 19, and 1 of the total number of transplants. dalignant cases were assigned as early or intermedi-
te/advanced risk for the overall population and for
he Remission/First Transplant patients based on
BMTR classiﬁcations.
tatistical Analysis
Kaplan-Meier estimates were used for probabili-
ies of engraftment, relapse, treatment-related mortal-
ty (TRM), relapse-free survival (RFS) for malignant
ases, and overall survival (OS), with standard deﬁni-
ions used for neutrophil ANC500, platelet 20K, and
latelet 50K engraftments. Myeloid engraftment was
eﬁned as the ﬁrst day of 3 consecutive days of an
bsolute neutrophil count (ANC) of 0.5  109/L.
latelet engraftment was deﬁned as the ﬁrst day of 7
onsecutive days of a platelet count of 20  109/L
aintained without transfusion for platelet 20K en-
raftment, or 50  109/L for platelet 50K engraft-
ent maintained without transfusion. The “unevalu-
ble” classiﬁcation was not used for any patient.
onor chimerism analysis was performed routinely at
ost transplant centers to conﬁrm engraftment. Log
ank test was used to compare different study popula-
ions.
ESULTS
B Inventory
With the focus on minorities CB collection, the
ombined inventory of 25,970 banked CB units at
temCyte U.S. and Taiwan (as of 5/31/2006) con-
isted mostly of non-Caucasian donor units with 63%
sians, 19% Hispanics, 13% Caucasians, 2% African-
mericans, and 3% donors of mixed heritage.
ostprocessing and Postthaw Recovery Rates for
lasma Depletion Processing
The effect of PD processing on postprocessing
ucleated cell recovery was examined on validation
B products. There was 0.1% total nucleated cell
TNC) loss (mean  0.072% and median 0.055%,
ange: 0-0.21%, standard deviation: 0.060%) incurred
y processing as measured by recovery in the dis-
arded plasma fraction (n  27); however, due to
ampling for various tests and archival purposes and
lumping after processing, an average of 98% nucle-
ted cell recovery was observed in the cryopreserved
nits (n  25,970) in the inventory. After thawing,
verage recovery of TNC, CD34 and viability were
5.81% (n  617), 81.88% (n  500), and 90.50%
n  617). Postthaw CFU testing yielded 78.99%
ostthaw recovery for CFU concentration on 121
onsecutive products selected for conﬁrmatory typing
hat have precryopreserved values. Due to lower post-
haw recovery for postthaw washed PD products (me-
ian 75% versus 95%), the postthaw TNC dose as
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Plasma-Depleted Cord Blood Transplantation 1349eported by transplant centers was lower for washed
roducts (median 5.3  107/kg and mean 7.8  107/
g) than unwashed products (median 5.6 107/kg and
ean 8.5  107/kg), although precryopreservation,
ashed CB products had higher median and mean
NC dose (6.1  107/kg and 8.0  107/kg) than
nwashed products (median TNC dose of 5.3  107/
g, mean TNC dose of 7.8  107/kg).
omparisons of PD and RD CB Inventories
The effect of CB processing techniques on post-
rocessing cell dose among the NMDP banks were
tudied (Table 1) [14,15]. Using data derived from the
MDP Cord Blood Bank Performance data as of
/30/2006 [19], the percentage of high cell dose units
mong the 2 types of inventories in the NMDP were
ompared. At all 3 TNC count levels (125, 150,
nd 200  107), the difference in proportions of
nventories with high cell dose was signiﬁcantly in
avor of PD inventory (P  .0001). Even after exclu-
ion of CB products with TNC count of 90  107
rom the analysis to rule out potential contribution of
ifferent TNC thresholds set by different CB banks,
he difference between PD CB and RD CB invento-
ies remained highly signiﬁcant at these TNC levels
P  .0001).
utcome Data Audits
The audit conducted by transplant centers was
erformed for the purposes of double checking the
ubmitted data and uncovering and correcting data
ubmission or data entry errors. The NMDP consis-
ently maintains a high data collection rate and ﬁnds
igh accuracy rates on their audits. Further, for data
ccuracy rate assessment, CIBMTR was employed. Of
he 2021 total PD CB data points for the 85 trans-
lants selected by CIBMTR for audit, outcome data
y the 2 PD CB banks in this study attained a 97.3%
verall data accuracy rate.
haracteristics of Transplanted PD CB Product
The cell dose and the number of HLA A/B/DR
atches between donor and recipient for all patients
able 1. Comparisons of Proportion of High Postprocessing Prefreeze
NC CB Units between the NMDP PD and RD CB Inventories as of
une 30, 2006
omparison of Postprocessing Prefeeze TNC Number For
lasma-Depleted and Red Cell-Depleted Cord Blood Products
CB with
TNC (107)
NMDP PD
CBB #
(% of 10,912 CB)
NMDP RD
CBB #
(% of 38,819 CB)
Test for
Diff. in
Proportions
t least 125 3772 (35) 8172 (21) P < .0001
t least 150 2157 (20) 3871 (10) P < .0001
t least 200 703 (6) 822 (2) P < .0001
MDP indicates National Marrow Donor Program; PD, plasma
wdepleted; CB, cord blood; RD, red cell depleted/reduced.nd for patients who were in remission and receiving
ﬁrst HCT are presented in Table 2. The mean and
edian nucleated cell doses for this series were 7.6 
07/kg and 5.6  107/kg, respectively. The number of
LA A/B/DR matches were similar to other series
eported by CB banks [16,20-25]. What is most strik-
ng is the high TNC number and TNC dose of the
ransplanted PD CB (Tables 2 and 3), which high-
ights the impact of a CBB inventory of high TNC
ose. In fact, the reported cell doses underrepresented
he combined cell dose used for the 11 double CBT
hat employed both PD and RD CB, because trans-
lant centers did not provide information on the RD
B unit, so that the cell dose of the second red
ell-depleted CB unit was not included in the TNC of
hese 11 transplants. The median and range of pre-
rocessing nucleated red blood cell percentage for the
ransplanted products are 6.9% and 0%-30.9%; the
ostprocessing nucleated red blood cell percentage
edian and range are 7.9% and 0%-31.7%.
haracteristics of Patient Population and
isease Indications
Table 3 provides information on the total patient
opulation and the subset of patients who were in
emission and receiving a ﬁrst HCT, as well as a
reakdown of the indications. These characteristics
ppear to be similar to other series by CB banks
16,20-25] or transplant centers and registries [1,6,21-
3,25-37].
nfusion Associated Adverse Reactions of
D CB Product
Analysis of infusion-associated adverse reactions
able 2. Postprocessing Prefreeze TNC Number and Dose of
ransplanted PD CB Product
ransplanted CB Products
ostprocessing Prefreeze TNC Number N %
ransplant CB with TNC below 100 107 20 17
ransplant CB with TNC between 100 and 149 107 34 29
ransplant CB with TNC below 150 and 199 107 32 27
ransplant CB with TNC above 200 107 32 27
Transplanted CB Products
Postprocessing Prefreeze TNC Dose N %
ransplants with TNC Dose below 2 107/kg 9 8
ransplants with TNC Dose between 2.0 and 2.9
107/kg 15 13
ransplants with TNC Dose between 3.0 and 3.9
107/kg 16 14
ransplants with TNC Dose between 4.0 and 4.9
107/kg 12 10
ransplants with TNC Dose between 5.0 and 5.9
107/kg 12 10
ransplants with TNC Dose above 6.0 107/kg 54 46
NC indicates total nucleated cell; CB, cord blood.ere separated by patients who received postthaw
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R. Chow et al.1350ashed products (W) and those who received CB that
ere not washed after thaw (NW). Events occurring
uring or after infusion include hypertension (6NW,
W), hives (1NW, 1W), nausea/vomiting (2NW), and
yspnea (1NW, 1W). Hemoglobinuria (9NW, 1W) is
n expected occurrence for PD CB because most red
lood cells lyse after thawing. Most symptoms attrib-
ted to DMSO administration were self-limiting or
asily managed. One patient developed seizure and
ncephalopathy, although relationship to infusion was
able 3. Patient Characteristics, CB Characteristics, Diagnosis, and Di
All
(
Median
ge (years) 7.3
eight (kg) 25
arnofsky Score 90
Days diagnosis to transplantation 498
Days follow-up surviving patients 704
refreeze TNC dose (107/kg) 5.6
C Postthaw TNC dose (107/kg) 4.6
ostthaw viability (%) per TC 75
aired postthaw recovery (%) 79
reprocessing CD34 dose (105/kg) 1.8
ost processing nRNBC (%) 7.9
n
dult patients (>16 years) 32
arger patients (>50 kg) 37
ale recipients 72
on-U.S. transplant center patients 42
ouble PD cord transplants 10
ouble PD/RD cord transplants 11
educed-intensity conditioning 19
/6 HLA A/B/DR matches* 18
/6 HLA A/B/DR matches* 35
/6 HLA A/B/DR matches* 50
-3/6 HLA A/B/DR matches* 15
alignant indications 87
ALL 38
AML 22
CML 8
MDS 8
JMML 2
Others 9
arly risk 21
ntermediate/advanced risk 46
isk unknown or not applicable 20
rior transplant 7
ransplanted during relapse 16
enign indications 31
emoglobinopathies 14
AA 5
WAS 5
Others 7
HLA Class I matches are at low resolution and class II are at hi
nucleated cells; PD, plasma depleted; RD, red cell depleted/redu
MDS, myelodysplastic syndromes; TC, transplant center; JMML
AA, aplastic anemia; WAS, Wiskott Aldrich syndrome.ncertain. Futcome Data—Engraftment, TRM, GVHD Rate,
elapse Rate, RFS, and OS
Table 4 summarizes the median age, weight, TNC
ose, CD34 dose, number of HLA matches, neutro-
hil (ANC500), platelet 20K and 50K engraftment,
elapse rate for malignant cases, 1-year TRM, 1-year
FS, and OS for all patients and for the various
ubsets of patients.
Neutrophil engraftment for all patients and for
emission/ﬁrst transplant patients are illustrated in
sk Factors
lants
8)
Remission First Transplant
(n  98)
Range Median Range
0.3-55 6.5 0.3-54
5-103 24 5-88
50-100 100 50-100
27-3553 450 27-3553
34-1502 393 116-1502
0.9-47 5.6 0.9-47
0.6-25 4.8 0.6-25
8-102 75 8-102
13-274 79 25-274
0.2-21 2.0 0.3-21
0-31.7 7.1 0-25.6
% n %
27 24 24
32 27 28
61 59 60
36 36 37
8 10 10
9 6 6
16 15 15
15 17 17
30 30 31
42 39 40
13 12 12
74 68 69
32 29 30
19 16 16
7 7 7
7 7 7
2 2 2
8 7 7
24 21 31
53 29 43
23 18 26
6 NA NA
14 NA NA
26 30 31
12 14 14
4 4 4
4 5 5
6 7 7
lution. NA indicates not applicable; CB, cord blood; TNC, total
L, acute myelogenous leukemia; CML, chronic myeloid leukemia;
ile myelomonocytic leukemia; ALL, acute lymphoblastic leukemia;sease Ri
Transp
n  11
gh reso
ced; AMigure 1A and B, respectively. The platelet 20K
Table 4. Summary of Transplant Characteristics and Outcome for the Various Cohorts
All
n  118
Remission
1st Xsplant
n  98
NMDP
n  58
Non-NMDP
n  60
US PD CBB
n  85
TW PD CBB
n  33
1X PD CBT
n  99
2X PD CBT
n  19
<50 kg
n  81
>50 kg
n  37
Benign
n  29
Malignant
n  89
Median age 8 7 7 9 9 6 6 18 4.3 27 4 10
Median weight 26 24 26 25 29 20 22 68 17 66 17 37
Median TNC dose (107/kg) 5.6 5.6 5.7 5.4 5.3 6.2 6.1 NA 7.6 3 7.7 4.4
Median CD34 cell dose
(105/kg) 1.8 2 1.9 1.8 1.7 2.4 2.4 NA 2.9 0.85 3.1 1.5
Median # HLA A/B/DR 4 4 4 4 4 4 4 4 5 4 4 4
ANC 500 90  3% 94  3% 94  3% 87  6% 93  3% 83  7% 90  3% 92  8% 92  4% 90  5% 90  7% 89  4%
% Engraftment 22.0 22.0 23.5 21.0 23.5 20.0 22.0 22.0 22.0 23.5 15.0 24.0
Median days P  .55 P  .81 P  .97 P  .58 P  .01
Platelet 20K 77  5% 81  5% 78  6% 75  8% 73  6% 90  6% 80  5% 58  14% 80  5% 71  10% 89  7% 72  6%
% Engraftment 49.5 49.5 55.0 44.5 53.0 43.0 49.0 55.0 51.0 42.0 47.5 52.5
Median days P  .35 P  .001 P  .25 P  .52 P  .008
1-Yr relapse 25  6% 19  6% 26  8% 24  9% 24  6% 32  14% 27  7% 18  11% 27  8% 22  9% 25  6%
P  .86 P  .29 P  .56 P  .64
1-Yr TRM 26  4% 20  4% 25  6% 26  6% 28  5% 18  7% 27  5% 21  10% 21  5% 33  8% 10  6% 31  5%
P  .89 P  .53 P  .77 P  .09 P  .07
1-Yr OS 65  5% 73  5% 62  7% 69  6% 63  6% 71  8% 63  5% 74  10% 72  6% 55  9% 90  6% 54  7%
P  .63 P  .72 P  .57 P  .05 P  .01
1-Yr RFS 51  6% 59  7% 53  8% 46  9% 51  7% 46  12% 47  7% 64  13% 51  8% 52  9% 50  6%
P  .27 P  .35 P  .39 P  .78
TRM indicates transplant related mortality; OS, overall survival; RFS, relapse free survival for malignant indications; All, All PD CBT; Remission 1st Xsplant, PD CB transplanted during remission
as ﬁrst transplant; NMDP, NMDP mediated PD CB transplant; Non-NMDP, PD CB transplant outside of the NMDP network; US CBB, PD CBT sourced from U.S. PD cord blood bank; TW
CBB, PD CBT sourced from Taiwan PD cord blood bank; 1X PD CBT, single cord blood transplants using PD CB; 2X PD CBT, double cord blood transplants using one or two PD CB; 50
kg, PD CBT for patients under 50 kg; 50 kg, PD CBT for patients 50 kg or over; Benign, PD CBT performed for nonmalignant indications; Malignant, PD CBT performed for malignant
indications.
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R. Chow et al.1352ngraftment for all patients and for remission/ﬁrst
ransplant patients are shown in Figure 1C and D,
espectively. ANC500 and platelet 20K and 50K en-
raftment for all patients were 90%  3%, 77% 
%, and 75%  5%, respectively. For the remission/
rst transplant patients, ANC500 and platelet 20K
nd 50K engraftment were 94%  3%, 81%  5%,
nd 80%  5%, respectively.
The ANC500 engraftment rates for the NMDP-
ediated PD CBT and non-NMDP-mediated PD
BT were similar (P  .55). CBT sourced from the
.S. and Taiwan PD CB banks were also similar (P 
81). Single PD CBT had similar engraftment rates as
ouble CBT with 1 or 2 PD CB units (P  .97).
nwashed products engrafted faster for ANC500 (20
ays versus 27 days) (log rank test; P  .02) and
latelets (47 days versus 54 days; log rank test; P 
0003).
Unlike most previous studies [22,23,26-27,29-37],
ransplants for adult weight recipients (50 kg) had
imilar engraftment rates as pediatric recipients
eighing 50 kg (P  .58 for ANC500 and .52 for
latelet 20K). However, transplants for patients with
igure 1. Kaplan-Meier estimates of the probability of neutrophil e
second panel from top) and platelet 20 K engraftment for C, all tra
anel).enign indications showed better engraftment than iransplants for malignancies (ANC500 P  .01; Plate-
et 20K P  .008).
TRM at 100 days was 16%  3% for all patients
n  118) and 10%  3% for remission ﬁrst trans-
lant cases (n  98). The 1-year TRM are summa-
ized in Table 4. Primary and secondary reported
auses of death include infection (50% of the cases),
elapse (25%), graft failure (7%), GVHD (7%), and
ther causes (25%). One-year TRM for NMDP me-
iated PD CBT and non-NMDP mediated PD CBT
ere similar (P  .89). Single PD CBT had similar
-year TRM as double CBT with 1 or 2 PD CB unit
P  .77). CBT sourced from StemCyte U.S. and
temCyte Taiwan had similar 1-year TRM (P  .53).
ransplants with washed and unwashed PD CB had
imilar 1-year TRM (P  .76). However, TRM for
ransplants for recipients weighing under 50 kg
rended toward a lower rate than those recipients
eighing 50 kg or above (P  .09).
The incidences of grade III-IV aGVHD and ex-
ensive chronic GVHD (cGVHD) among all patients
ere 13%  4% and 17%  6%, respectively.
For malignancies, 1-year relapse rate for the var-
ent. For A, all transplants (top panel); B, remission ﬁrst transplants
s (third panel from top); and D, remission ﬁrst transplants (bottomngraftm
nsplantous subgroups were all similar: NMDP-mediated
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Plasma-Depleted Cord Blood Transplantation 1353ransplants and non-NMDP-mediated transplants
P  .86), single PD CBT and double CBT with 1 or
PD CB unit (P  .56), recipients under 50 kg and
ecipients 50 kg or above (P  .64), transplants with
ashed and unwashed PD CB (P  .40), and CBT
ourced from StemCyte U.S. and Taiwan (P  .29).
The 1-year RFS of all malignant patients (n  85)
as 51% 6% (Figure 2A), and that of the remission/
rst transplant patients with malignancies (n  67)
as 59%  7% (Figure 2C). The 1-year OS rate for
ll patients (n 118) was 65% 5% (Figure 2B), and
hat for remission/ﬁrst transplant patients (N  98)
as 73%  5% (Figure 2D).
Transplants for recipients under 50 kg had a
-year OS of 72%  6%, whereas those recipients
eighing 50 kg or above had a lower 1-year OS at
5%  9% (P  .05). In contrast, RFS for malignant
ndications were similar at 51%  8% for patients
eighing 50 kg and 52%  9% for patients weigh-
ng 50 kg or more (P  .78).
For the other subsets, 1-year RFS and OS were
imilar: for the NMDP-mediated PD CBT versus
on-NMDP-mediated PD CBT (P .27 for RFS and
 .63 for OS), single PD transplants versus double
igure 2. All patients—Kaplan-Meier estimates of the probability
urvival of all patients (second panel from top); C, relapse-free surv
verall survival for remission ﬁrst transplant patients (bottom paneransplants with 1 or 2 PD CB unit (P  .39 for RFS [nd P  .57 for OS), and CB from StemCyte U.S.
ersus Taiwan (P  .35 for RFS and P  .72 for OS).
ISCUSSION
Although there have been several published re-
orts on the clinical use of PD CB for HCT [8,28,38-
4], this is the ﬁrst large patient series. The NMDP,
IBMTR, and transplant centers audited the outcome
ata in this report. To our knowledge, this is the ﬁrst
utcome report by a CB bank that has employed
xternal audits. This series is also unusual in terms of
he high proportion of international and minority
ransplants as well as the high mean and median cell
oses that were observed. The high neutrophil and
latelet 20K engraftment probability for both pediat-
ic (92% 4% and 80% 5%) and adult (90% 5%
nd 71%  10%) patients observed in this study is
lso worth noting.
High cell dose is recognized as a critical determi-
ant of success for CBT [36], and limited cell doses
ave hampered the use of CB for transplantation in
dults. Although recommendations as recent as 2003
lapse-free survival of all malignant patients (top panel); B, overall
r remission ﬁrst transplant patients (third panel from top); and D,of A, re
ival fo26] suggested that a minimum acceptable cell dose
s
t
e
u
n
r
o
c
t
t
g
e
e
C
p
m
a
T
c
T
i
C
5
w
d
i
c
t
i
p
o
t
c
c
a
p
t
t
c
t
c
r
w
p
s
d
p
s
u
b
u
b
o
c
w
c
c
f
c
C
p
o
p
c
m
s
a
a
c
t
a
w
t
e
d
e
b
t
N
d
c
o
N
p
t
f
v
N
t
t
e
b
r
t
[
d
r
r
2
T
u
s
s
C
n
t
P
a
y
R. Chow et al.1354hould be 1.5  107 nucleated cells/kg to reduce time
o myeloid recovery and increase the probability of
ngraftment, other recommendations suggest that CB
nits should be selected on the basis of a minimum
ucleated cell dose of 3  107 [27] to 4  107/kg [29]
ecipient body weight to obtain acceptable clinical
utcomes. It has been reported that only 12% of the
urrent inventory in established public CB banks con-
ains sufﬁcient cells to deliver such cell doses to pa-
ients weighing 60 kg; therefore, alternative strate-
ies to increase cell dose for larger patients need to be
xplored [27].
To minimize cell loss during processing, we have
liminated the step of red blood cell reduction from
B prior to cryopreservation and plasma depletion
rocessing was utilized instead. This process mini-
izes nucleated cell loss during processing to 0.1%
s measured by cell content of the discarded plasma.
his minimal level of cell loss is unattainable using
urrent red cell reduction techniques [14,15,17,18].
o test if plasma depletion processing makes a signif-
cant improvement in cell dose to actual inventories of
B banks, the 2 types of CB inventories of almost
0,000 CB of the 18 CB banks of the NMDP network
ere compared. As the largest analysis comparing cell
oses of different inventories, it showed that PD CB
nventory has signiﬁcantly higher proportions of high
ell dose CB products than the RD CB inventory in
he NMDP network. The possibility that the PD CB
nventories started off with a higher collection or
reprocessing cell dose can be excluded because most
f the products were collected during a period when
he minimal volume threshold was 40 to 50 mL. We
onclude that utilizing plasma depletion allows for
ryopreservation of CB units with higher cell doses,
nd therefore has the potential of making a higher
ercentage of units collected available for transplan-
ation. The high cell dose of the PD inventory appears
o be directly correlated with the high prefreeze nu-
leated cell dose of the transplanted units observed in
his study. In parallel processing studies using identi-
al samples, the nucleated cell, CD34 cell, and CFU
ecoveries appear to be 24%, 23%, and 34% higher
ith plasma-depleted products than red cell-depleted
roducts (manuscript in preparation); however, this
tudy cannot address whether the resultant higher cell
ose of plasma depleted products translates into im-
roved clinical outcome without rigorous compari-
ons with patients transplanted with red cell-depleted
nits.
Although anecdotal reports and abstracts have
een published on the use of plasma-depleted CB
nits [8,28,38-44], adequate data have not previously
een available to evaluate the safety and effectiveness
f units stored after plasma depletion. A rigorous
omparison of results using PD CB versus RD units
as not possible in the current study because out- Pomes using RD units were not available to us. Be-
ause of potential center effects, we have refrained
rom comparing our data against individual transplant
enter studies. However, the results of CBT using PD
B that are presented in this study are at least com-
arable to those presented in other reviews of CBT
utcomes from CB banks [7,16,20-25,37] or trans-
lant registries [1,22-24,26-36,45]. This includes in-
idence and speed of neutrophil and platelet engraft-
ent, TRM, relapse rate, OS, and disease-free
urvival rates, the incidence and severity of aGVHD
nd cGVHD.
Various other potential explanations for the favor-
ble outcomes observed in this study were systemati-
ally examined and excluded. For example, the poten-
ial for favorable reporting bias by transplant centers is
theoretic problem that all registries or CB banks face
hen collecting and analyzing outcome data. The way
o exclude signiﬁcant favorable reporting bias is with
xtensive on-site audits to ensure accuracy or high
ata collection rate. In this study, data accuracy was
nsured through audits by both transplant centers and
y external agencies—CIBMTR and NMDP. Half of
he transplants in this study were facilitated by
MDP, which collected, provided, and audited this
ata subset. Because the NMDP data subset is 91%
omplete, the potential of withholding unfavorable
utcome data is minimal; therefore, for this study, the
MDP data were considered the “gold standard,” and
recludes signiﬁcant favorable reporting bias. Because
he non-NMDP transplant outcome was not different
rom those of the NMDP transplants, signiﬁcant fa-
orable reporting bias can be ruled out in the non-
MDP cohort and in the combined dataset.
A beneﬁcial inﬂuence of double CBT [3-5,7] to
he outcome in this study was considered unlikely due
o the low percentage of double cords and because
ngraftment and survival outcomes of single and dou-
le CBT were comparable in this series (Table 4). The
esults of the double CBT using PD CB were similar
o those reported by other groups that used RD CB
3-5]. However, similarity in engraftment between
ouble and single CBT appears to differ from earlier
eports [3-5,7] and to be consistent with the most
ecent Minnesota experience (Wagner and Brunstein,
007 International CB Transplantation Symposium).
he high cell dose for single CBT may have contrib-
ted to the favorable outcome for single CBT ob-
erved in both studies. A positive contribution of a
econd RD CB from another CB bank in the double
BT setting was considered unlikely because the
umber of mixed PD/RD double CBT were limited
o 9%. Moreover, engraftment and survival of double
D CB transplant were signiﬁcantly better (ANC500
nd platelet 20K engraftment) or trended better (1-
ear OS) than double CBT with the combination of a
D CB and an RD CB (data not shown).
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Plasma-Depleted Cord Blood Transplantation 1355The patient characteristics in this series appear to
e comparable to other series reported by CB banks in
he literature [1,6-7,16,21-25], including sex, age,
eight, percentage of malignancies, and number of
LA mismatches. This is expected, because CB banks
o not have the option to select patients or centers, so
n relatively large studies, most patient, disease, HLA,
nd other characteristics would conform to standard
istributions. One signiﬁcant difference appears to be
he very high percentage of minority patients and
rocedures performed at non-U.S. centers, both re-
ated to the minority and international focus of the 2
B banks employing plasma depletion processing.
iven this difference and the outstanding CBT results
y the University of Tokyo group in Japan [45], the
otion that Asians may experience better outcomes
fter CB transplantation was examined. The hypoth-
sis was rejected as a signiﬁcant contributor to this
tudy because, unlike the 100% Asian patient compo-
ition of the University of Tokyo study [45], only 33%
f the transplants in this study were for Asian patients.
oreover, transplants for Asians experienced out-
omes similar to those for other patients in this study
data not shown).
The most noticeable difference of this series from
revious studies was the unusually high prevalence of
oth high prefreeze and postthaw cell doses, which, as
hown earlier, may be attributed to the generally
igher cell dose in the inventory. This higher cell
umber of units in the PD inventory increases the
robability of a CB unit being picked having a high
ell dose, contributing to the high prevalence of ex-
ellent prefreeze cell doses used in transplants (Table
). Moreover, in centers that have opted not to wash,
he additional 10%-30% loss due to wash is avoided
8-12], contributing to the minimal loss in the post-
haw numbers with those transplants. Similar to our
arlier reports [8], we conﬁrm here safety of PD CB
nd signiﬁcantly improved engraftment speed and
robability using PD units that are not washed versus
D units that are washed after thawing. The outcome
f this study shows that, like other cryopreserved stem
ell products, with proper premedication and hydra-
ion prior to infusion [46-50], PD CB with or without
ostthaw wash, is safe with occasional infusion reac-
ions that are mostly self-limited and easily treated or
esolved without treatment. Although no cryopre-
erved stem cell products can be used without rare
ccurrences of serious reactions, with attention to
MSO dose and comorbid conditions, such untoward
ncidents can be minimized. Like all cryopreserved
roducts, the recommended threshold of 1 g DMSO
er kilogram of recipient body weight minimizes the
ossibility of adverse reactions and should not be
xceeded [35,44,46-49]. For this reason, all PD prod-
cts are supplied with information regarding the vol-
me or mass of DMSO in the product.There were no clear observed beneﬁts of perform-
ng postthaw wash for PD CB. Transplants with PD
B not washed were at least as efﬁcacious as washed
D CB with respect to TRM, relapse rate, 1-year OS,
nd RFS. Moreover, to our knowledge, this is the ﬁrst
eport that washing appears to have a negative impact
n the incidence and speed of neutrophil and platelet
ngraftment. Stiff et al [9] concluded that, when using
nonwash postthaw procedure, few viable cells are
ost, allowing successful CBT at lower postthaw nu-
leated cell doses than would otherwise be possible.
he St. Louis group also reported satisfactory viability
nd CFU recovery with unwashed and undiluted CB
ithin an hour after thawing [50]—within the usual
eriod when CB infusion would be completed after
hawing. Therefore, for the PD CB unit, we highly
ecommend that in most instances, cell loss be mini-
ized at the transplant center by eliminating the
ashing of the product before infusion. Appropriate
xceptions may include patients with histories of sen-
itivity to DMSO, small children (15 kg) resulting in
nwashed DMSO dose of 1 g/kg recipient weight, and
atients with compromised renal function [46-49].
In conclusion, transplantation using PD CB
nits is safe and effective for diverse patients; elim-
nating red cell depletion increases the nucleated
ell recovery of CB processing and contributes to a
igher percentage of units collected available for
ransplantation. The low TRM, high engraftment,
S, and RFS are not surprising given the high cell
oses used in this study. Although high cell dose
ppears to be the most logical hypothesis to explain
ur ﬁndings, rigorous prospective trials or matched
air retrospective analysis with and without adjust-
ent for cell dose between plasma-depleted CB and
ed cell-depleted CB will be necessary to prove a
ausal relationship.
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